
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR30206
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DR30206 + Standard Therapy Preliminary Safety and Efficacy In GI Cancer
Details : DR30206 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Gastrointestinal Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 09, 2025
Lead Product(s) : DR30206
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Junbo Ge
Deal Size : Inapplicable
Deal Type : Inapplicable
DR10624 Safety and Efficacy In Hypertriglyceridemia and Carotid Plaque
Details : DR10624 is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2025
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Junbo Ge
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of DR10624 Injection in MASLD & MetALD
Details : DR10624 is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 17, 2025
Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Doses First Patient in DR10624 Phase 2 Liver Disease Study
Details : DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor. It is being evaluated for the treatment of liver fibrosis associated with MASLD.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624
Details : DR10624 is first-in-class, tri-specific agonist targeting FGF21R, GCGR, GLP-1R. It is being evaluated for the treatment of severe hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Doses First Patient in Phase 2 Study of DR10624 for Hypertriglyceridemia
Details : DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR & FGF21R, it is being investigated for the treatment of obesity and hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DR10624 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 15, 2024
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zhejiang Doer Completes Phase 1b/2a Trial Enrollment for DR10624 in Obese Subjects
Details : DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR & FGF21R, it is being investigated for the treatment of obesity and hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 05, 2024
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : DR30206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR, and FGF21R, which is investigated for the treatment of obesity and hypertriglyceridemia in New Zealand.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
